NEWS
Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients
Cadrenal Therapeutics (Nasdaq: CVKD) highlighted a recently published manuscript in the Journal of Cardiac Failure, evaluating the relationship between time in therapeutic range (TTR) management quality and clinical outcomes for left ventricular assist device (LVAD) patients. The findings emphasize the need for improved anticoagulation therapy beyond warfarin to reduce gastrointestinal bleeding, a common complication in LVAD patients.
Key points:
Tecarfarin, a novel vitamin K antagonist (VKA), may offer more stable and effective anticoagulation for LVAD patients
A secondary analysis of the ARIES-HM3 trial showed a 47% reduction in bleeding risk for patients with a TTR above the median
Lower TTRs were associated with threefold more sub-therapeutic INRs than supra-therapeutic INRs
Cadrenal Therapeutics is developing tecarfarin as a late-stage, next-generation VKA oral and reversible anticoagulant
Key points:
Tecarfarin, a novel vitamin K antagonist (VKA), may offer more stable and effective anticoagulation for LVAD patients
A secondary analysis of the ARIES-HM3 trial showed a 47% reduction in bleeding risk for patients with a TTR above the median
Lower TTRs were associated with threefold more sub-therapeutic INRs than supra-therapeutic INRs
Cadrenal Therapeutics is developing tecarfarin as a late-stage, next-generation VKA oral and reversible anticoagulant
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2490Followers
107Following
27KVisitors
Follow